Eventide Healthcare & Life Sciences Fund Named a WSJ Category King

Wednesday, July 18, 2018 Lifestyle News
Email Print This Page Comment bookmark
Font : A-A+

BOSTON, July 17, 2018 /PRNewswire/ -- The Eventide Healthcare & Life Sciences Fund (NASDAQ: ETIHX) was named as a "Category

King" by The Wall Street Journal for the one-year period ending June 29, 2018. The award recognizes the top 10 funds in each equity category for one-year total return. The Eventide Healthcare & Life Sciences
Fund ranked #1 in the Health & Biotech category out of 98 funds.

The Eventide Funds are guided by a unique approach that seeks to deliver market outperformance to investors by investing in companies creating compelling value for the world. Eventide CIO and lead portfolio manager for the Fund Finny Kuruvilla, MD PhD commented: "We founded Eventide with a vision of 'investing that makes the world rejoice.' Nowhere is this vision more clearly seen than in biotechnology where human creativity is being channeled to eradicate devastating diseases. Our investors take part in helping give longer life and improved quality of life to others. You can picture the rejoicing."    

Eventide Healthcare & Life Sciences Fund analyst Agustin Mohedas, PhD described the Fund's approach: "Advances in science and medicine have led to technological innovations that are now being applied to large unmet medical needs. Our investors participate in taking these technological innovations to market through new treatments that have the potential to create tremendous value for patients and society."

The investment objective of the Eventide Healthcare & Life Sciences Fund is to deliver long-term capital appreciation to investors by investing in healthcare and life sciences companies. The Fund concentrates investments in the drug-related industries, investing in companies with the potential to appreciate in value if positive data is released regarding clinical trials and FDA feedback, and through market acceptance of products.

The Eventide Healthcare & Life Sciences Fund is managed by Eventide Asset Management, a Boston-based registered investment adviser practicing "investing that makes the world rejoice."

The Wall Street Journal rankings are not intended to constitute investment advice. Rather, you should use the rankings for informational purposes only. Rankings are only one form of performance measurement. Past performance is no guarantee of future results.

The Wall Street Journal Category King is awarded to the top 10 investments in their Lipper Category based on one-year total return absolute rank. The award does not account for sales loads, where applicable. Where a Fund offers multiple share classes, the award is designated for the largest share class by assets under management.

The Fund offers other share classes for which rankings may differ based on fees: NASDAQ: ETNHX, NASDAQ: ETAHX, and NASDAQ: ETCHX.

Registration of an investment adviser does not imply a certain level of skill or training. The above expresses the views of Eventide Asset Management, LLC, and there is no guarantee that such views are accurate. Eventide's approach may not produce the desired results.

Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results. The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund's ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency – fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks.

An investor should consider a Fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information can be found in the prospectus, which can be obtained at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Please read the prospectus carefully before investing. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.

Fund contact:Jason MyhreDirector of Marketing877-771-EVEN (3836), x56

Cision View original content:http://www.prnewswire.com/news-releases/eventide-healthcare--life-sciences-fund-named-a-wsj-category-king-300682431.html

SOURCE Eventide Asset Management



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store